A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death

Recombinant soluble TRAIL and agonistic antibodies against TRAIL receptors (DR4 and DR5) are currently being created for clinical cancer therapy, due to their selective killing of cancer cells and high safety characteristics. However, resistance to TRAIL and other targeted therapies is an important...

Descripción completa

Detalles Bibliográficos
Autores principales: Bucur, Octavian, Gaidos, Gabriel, Yatawara, Achani, Pennarun, Bodvael, Rupasinghe, Chamila, Roux, Jérémie, Andrei, Stefan, Guo, Bingqian, Panaitiu, Alexandra, Pellegrini, Maria, Mierke, Dale F., Khosravi-Far, Roya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426715/
https://www.ncbi.nlm.nih.gov/pubmed/25962125
http://dx.doi.org/10.1038/srep09893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426715/
https://www.ncbi.nlm.nih.gov/pubmed/25962125
http://dx.doi.org/10.1038/srep09893

Ejemplares similares